- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06094790
A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
An Open-Label, Repeat-Dose Study to Evaluate the Pharmacokinetics of Orally Administered CORT125134 Using the Current Capsule Formulation in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Initially, subjects will be enrolled into 2 cohorts each of 8 subjects (Cohort 1 and Cohort 2) to receive CORT125134 at 150 mg or 250 mg, respectively. Data from Cohorts 1 and 2 will be evaluated to select dose levels for Cohort 3 and optional Cohort 4.
The secondary objective of the study is to characterize the plasma PK profile of CORT125134 metabolites in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33126
- Quotient Sciences, Miami, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Give written informed consent
- Be healthy males or non-pregnant, non-lactating healthy females
- Must agree to use an adequate method of contraception as described in the study protocol
- Have a body mass index (BMI) of 18 to 32 kg/m^2, inclusive and body weight more than 50 kg (110 pounds)
- Be willing to comply with study restrictions as described in study protocol
- Be able to comply with the requirements of the entire study
- Be judged to be in good health, based on the results of medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory findings
- Have suitable veins for multiple venipuncture/cannulation
Exclusion Criteria:
- Be an employee or immediate family member of the Clinical Research Unit or Corcept
- Have been previously enrolled in this study
- Have multiple drug allergies, or be allergic to any of the components of study drug
- Have a condition that could be aggravated by glucocorticoid blockade (eg, asthma, any chronic inflammatory condition)
- In the 1 year before study drug administration, have a history of drug or alcohol abuse
- In the 6 calendar months before study drug administration, on average: have smoked more than 5 cigarettes/day, consumed more than 14 units (female) or 21 units (male) of alcohol/week (1 unit/drink = 5 ounces of wine, or 12 ounces of beer, or 1.5 ounces of hard liquor), consumed licorice or other glycyrrhetic acid derivatives regularly, in the judgement of the Investigator
- In the 2 calendar months before study drug administration, have donated/ lost blood or plasma in excess of 400 mL
- In the 30 days before study drug administration, have participated in another clinical trial of a new chemical entity or a prescription medicine
- Have a positive test for alcohol or drugs of abuse at Screening or admission
- Have a positive test for exogenous glucocorticoids at Screening
- Have clinically-relevant abnormal findings on vital signs, physical examination, laboratory screening tests, or 12-lead ECG, at Screening and/or before first dose
- Have any medical or social reasons for not participating in the study raised by their primary care physician
- Have any other condition that might increase the risk to the individual or decrease the chance of obtaining satisfactory data, as assessed by the Investigator
- Have taken any prohibited prior medication, as described in study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Subjects will receive CORT125134 150 mg once daily for 14 days
|
CORT125134 150 mg (3 X 50 mg current capsule formulation)
|
Experimental: Cohort 2
Subjects will receive CORT125134 250 mg once daily for 14 days
|
CORT125134 250 mg (5 X 50 mg current capsule formulation)
|
Experimental: Cohort 3
Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1 and 2
|
CORT125134 current capsule formulation, dose to be determined
|
Experimental: Cohort 4 (optional)
Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1, 2, and 3, if it is considered that this cohort would aid achievement of the study objectives
|
CORT125134 current capsule formulation, dose to be determined
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the concentration-time curve over a dose-interval of plasma CORT125134 (AUCtau)
Time Frame: Predose and at serial timepoints over a dose-interval following dosing on Days 1, 7, and 14
|
Predose and at serial timepoints over a dose-interval following dosing on Days 1, 7, and 14
|
|
Maximum concentration of plasma CORT125134 (Cmax)
Time Frame: Predose and at serial timepoints up to 24 hours following Day 1 and Day 7 dosing, and at serial timepoints up to 120 hours following Day 14 dosing
|
Predose and at serial timepoints up to 24 hours following Day 1 and Day 7 dosing, and at serial timepoints up to 120 hours following Day 14 dosing
|
|
AUC from the time of dosing until 24 hours later of plasma CORT125134 (AUC0-24h)
Time Frame: Predose and at serial timepoints up to 24 hours following dosing on Days 1, 7, and 14.
|
Statistical analysis of these data will be used to estimate the highest oral dose of CORT125134 current capsule formulation steady state AUC0-24h of plasma CORT125134.
|
Predose and at serial timepoints up to 24 hours following dosing on Days 1, 7, and 14.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Andreas Moraitis, Corcept Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CORT125134-453
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on CORT125134 150 mg
-
Massachusetts General HospitalCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Corcept TherapeuticsCompletedHepatic ImpairmentUnited States
-
Novartis PharmaceuticalsCompletedHypertensionUnited States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
-
Georgetown UniversityUnknown
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-type PsoriasisUnited States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
-
Samsung Medical CenterCompletedStomach NeoplasmsKorea, Republic of
-
Bill & Melinda Gates Medical Research InstituteNot yet recruitingHealthy VolunteersKenya, Uganda
-
Fondazione OncotechNot yet recruiting
-
EMD SeronoTerminatedLupus Erythematosus, SystemicUnited States, Korea, Republic of, Bulgaria, Argentina, Mexico, Italy, Spain, Philippines, Germany, Czechia, Chile, Poland, Peru, United Kingdom, South Africa, Brazil, Russian Federation
-
Corcept TherapeuticsCompleted